Suzanne M. Morris, Dayton M. Petibone, Wei-Jiun Lin, James J. Chen, Benedetto Vitiello, Kristine L. Witt and Donald R. Mattison The genetic toxicity of methylphenidate: a review of the current literature Journal of Applied Toxicology 32
The symptoms of Attention Deficit/Hyperactivity Disorder (ADHD) are effectively treated with methylphenidate (MPH). In 2005, reported increases in cytogenetic damage in the lymphocytes of MPH-treated pediatric patients caused world-wide concern. Numerous studies were initiated to verify or refute the findings. As reviewed in this communication, neither the laboratory animal nor human subject studies found an increase in MPH-induced genetic damage. The subsequent studies do not support the initial hypothesis that MPH treatment increases the risk of genetic damage in ADHD patients.
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf